Buckingham Capital Management Inc. Sells 1,645 Shares of Eli Lilly and Company (NYSE:LLY)

Buckingham Capital Management Inc. reduced its position in Eli Lilly and Company (NYSE:LLYFree Report) by 10.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,290 shares of the company’s stock after selling 1,645 shares during the period. Buckingham Capital Management Inc.’s holdings in Eli Lilly and Company were worth $6,702,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Fairfield Bush & CO. bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $107,000. Roundview Capital LLC boosted its holdings in shares of Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after buying an additional 53 shares in the last quarter. Merit Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $210,000. NewEdge Advisors LLC boosted its stake in Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after purchasing an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter worth approximately $561,000. 81.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. Barclays lifted their target price on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 9th. Jefferies Financial Group raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price target for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. Credit Suisse Group raised their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 9th. Finally, Bank of America raised their price target on shares of Eli Lilly and Company from $500.00 to $600.00 in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $532.78.

View Our Latest Report on Eli Lilly and Company

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,156 shares of Eli Lilly and Company stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the sale, the insider now owns 101,387,286 shares of the company’s stock, valued at approximately $46,037,938,826.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 34,156 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the transaction, the insider now owns 101,387,286 shares of the company’s stock, valued at approximately $46,037,938,826.88. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now directly owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. Insiders have sold a total of 1,010,309 shares of company stock valued at $21,095,701,670 in the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $575.50 on Monday. The firm has a market cap of $546.32 billion, a PE ratio of 80.06, a PEG ratio of 2.47 and a beta of 0.32. The firm has a fifty day moving average of $512.56 and a 200 day moving average of $439.28. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. Eli Lilly and Company has a one year low of $296.32 and a one year high of $601.84.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The company had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $7.58 billion. During the same quarter in the previous year, the company posted $1.25 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were paid a dividend of $1.13 per share. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.